Long-term cancer risk of the anorectal cuff following restorative proctocolectomy assessed by p53 expression and cuff dysplasia

Colorectal Disease

Volumn 9, Issue 4, 2007, Pages 321-327

  Coull, Dom B ^a   Lee, F D ^a   Anderson, J H ^a   McKee, R F ^a   Finlay, I G ^a   Dunlop, M G ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Colorectal cancer; Dysplasia; P53; Restorative proctocolectomy; Ulcerative colitis

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER RISK; COLITIS; COLON BIOPSY; COLON RESECTION; CONTROLLED STUDY; FOLLOW UP; GENERAL ANESTHESIA; HEMORRHOIDECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEUM POUCH; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECTUM CARCINOMA; RECTUM DISEASE; RECTUM DYSPLASIA; ULCERATIVE COLITIS;

ADULT; BIOPSY; CELL TRANSFORMATION, NEOPLASTIC; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; MALE; PRECANCEROUS CONDITIONS; PROCTOCOLECTOMY, RESTORATIVE; PROSPECTIVE STUDIES; RISK FACTORS; SURGICAL STAPLING; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147120524     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2006.01118.x     Document Type: Article

References (46)

1. McCourtney JS, Finlay IG. Totally stapled restorative proctocolectomy. Br J Surg 1997; 84: 808-12.
2. Williams NS. Restorative proctocolectomy is the first choice elective surgical treatment for ulcerative colitis. Br J Surg 1989; 76: 1109-10.
3. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. Br Med J 1978; 2: 85-8.
4. Lavery IC, Tuckson WB, Fazio VW, Oakley JR, Church JM, Milsom JW. Pouch surgery - the importance of the anal transition zone. Can J Gastroenterol 1990; 4: 428-31.
5. Goldman H. Significance and detection of dysplasia in chronic colitis. Cancer 1996; 78: 261-3.
6. Nugent FW, Haggitt RC, Gilpin PA. Cancer surveillance in ulcerative colitis. Gastroenterology 1991; 100: 1241-8.
7. Riddell RH, Goldman H, Ransohoff DF et al. Dysplasia in inflammatory bowel disease: Standardised classification with provisional clinical applications. Hum Pathol 1983; 14: 931-68.
8. Coull DB, Lee FD, Henderson AP, Anderson JH, McKee RF, Finlay IG. Risk of dysplasia in the columnar cuff after stapled restorative proctocolectomy. Br J Surg 2003; 90: 72-5.
9. Lashner BA. (1994) Cancer surveillance in ulcerative colitis: Much ado about little? In: Difficult Decisions in Digestive Diseases (eds Barkin JS, Rogers AL), pp. 357-61. Mosby, St. Louis.
10. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343: 71-4.
11. Connell WR, Lennard-Jones JE, Williams CB et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-44.
12. Lynch DAF, Lobo AJ, Sobala GM et al. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993; 34: 1075-80.
13. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994; 107: 1196-9.
14. Connell WR, Talbot IC, Harpaz N et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994; 35: 1419-23.
15. Baker SJ, Pressinger AC, Jessup JM et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Advances in Brief 1990; 50: 7717-22.
16. Burmer GC, Rabinovitch PS, Haggitt RC et al. Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of p53 allele. Gastroenterology 1992; 103: 1602-10.
17. Fogt F, Vortmeyer AO, Goldman H, Giordano RJ, Merino MJ, Zhuang Z. Comparison of genetic alterations in colonic adenoma and ulcerative colitis associated dysplasia and carcinoma. Hum Pathol 1998; 29: 131-6.
18. Harpaz N, Peck AL, Yin J et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 1994; 25: 1069-74.
19. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104: 1633.
20. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, Burmer GC. Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107: 369-78.
21. Lashner BA, Shapiro BD, Husain A, Goldblum JR. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 1999; 94: 456-62.
22. Serafini EP, Kirk AP, Chambers TJ. Rate and pattern of epithelial cell proliferation in ulcerative colitis. Gut 1981; 22: 648-52.
23. Bass IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
24. Bartek J, Bartkova J, Vojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature for a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
25. Crohn BB, Rosenberg H. The sigmoidoscopic picture of chronic ulcerative colitis. Am J Med Sci 1925; 170: 220-3.
26. Thompson-Fawcett MW, Mortensen NJ. Anal transitional zone and columnar cuff in restorative proctocolectomy. Brit J Surg 1996; 83: 1047-55.
27. Schmitt SL, Wexner SD, Lucas FV, James K, Nogueras JJ, Jagleman DG. Retained mucosa after double-stapled ileal reservoir and ileoanal anastomosis. Dis Colon Rectum 1992; 35: 1051-6.
28. O'Riordain MG, Fazio VW, Lavery IC, Remzi F, Fabbri N, Meneu J, Goldblum J, Petras RE. Incidence and natural history of dysplasia of the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 2000; 43: 1660-5.
29. Emblem R, Bergan A, Larsen S. Straight ileoanal anastomosis with preserved anal mucosa for ulcerative colitis and familial polyposis. Scand J Gastroenterol 1988; 23: 913-9.
30. Slors JF, Ponson AE, Taat CW, Bosma A. Risk of residual rectal mucosa after proctocolectomy and ileal pouch-anal reconstruction with the double-stapling technique. Dis Colon Rectum 1995; 38: 207-10.
31. Haray PN, Amarnath B, Weiss EG, Nogueras JJ, Wexner SD. Low malignant potential of the double stapled ileal pouch-anal anastomosis. Br J Surg 1996; 83: 1406.
32. Remzi FH, Fazio VW, Delaney CP et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis. Dis Colon Rectum 2003; 46: 6-13.
33. Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989; 20: 1008-14.
34. Ajioka Y, Watanabe H, Matsuda K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: Immunohistochemical study. J Gastroenterol 1995; 30 (Suppl. VIII): 33-5.
35. Burmer GC, Crispin DA, Kolli VR et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer commun 1991; 3: 167-72.
36. Greenwald BD, Harpaz N, Yin J et al. Loss of heterozygosity affecting the p53, Rb and mcc/apc tumour suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992; 52: 741-5.
37. Taylor HW, Boyle M, Smith SC et al. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg 1993; 80: 442-4.
38. Bartek J, Bartkova J, Lukas J et al. Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993; 169: 27-34.
39. Rubio MP, von Diemling A, Yandell DW et al. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993; 53: 3465-7.
40. Helander SD, Peters MS, Pittkelow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993; 29: 741-8.
41. Scarpa A, Capelli P, Mukai K et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol 1993; 142: 1534-43.
42. Thomson AM, Anderson TJ, Condie A et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992; 50: 528-32.
43. Holzmann K, Klump B, Borchard F, Hsieh C-J, Kuhn A, Gaco V, Gregor M, Porschen R. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int J Cancer 1998; 76: 1-6.
44. Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989; 34: 1536-41.
45. Rubin CE, Haggit RC, Brumer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103: 1611-20.
46. Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B. DNA aneuploidy in ulcerative colitis: Reproducibility, topographic distribution and relation to dysplasia. Gastroenterology 1992; 102: 1149-54.